Register / Log In

Hospital/Health-System Pharmacy

Stroke prevention in the elderly may be excessive, researcher says
Patients more than 80 years old are being “over-treated” for stroke prevention with statins and antihypertensive drugs, and doctors need to actively rethink their priorities and beliefs about stroke prevention, according to a new study published in Evidence Based Medicine.
FDA panels vote against OTC Primatene HFA inhaler
FDA advisors decided against recommending over-the-counter (OTC) marketing approval of Primatene HFA inhaler (Armstrong Pharmaceuticals) for the temporary relief of mild symptoms of intermittent asthma in patients 12 years and older, at last week’s joint meeting of the FDA’s Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee.
FDA approves treatment for neurogenic orthostatic hypotension
FDA approved droxidopa (Northera, Chelsea Therapeutics) capsules for the treatment of neurogenic orthostatic hypotension (NOH). NOH is a rare, chronic and often debilitating condition that is associated with Parkinson's disease, multiple-system atrophy, and pure autonomic failure.
New SSRI approved in last quarter of 2013
FDA approved vortioxetine as oral tablets indicated for the treatment of major depressive disorder.
Same-day care, capacity key to managing flu season
Last year’s flu season brought chills to some providers; experts say planning, education are even more critical now
AAP report updates use of medications during breast-feeding
The American Academy of Pediatrics (AAP) clinical report released this week provides guidance for physicians about the use of psychotropic drugs, substance abuse treatments, narcotics, galactagogues, herbal products, and vaccines in breast-feeding women and the potential effects on the breast-feeding infant.
The few words that change everything
Some thoughts about the things that count
Long-term data reinforce safety profile of dabigatran
Results from the RELY-ABLE trial, the RE-LY extension study, support the long-term safety profile of dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) 150 mg twice daily in patients with nonvalvular atrial fibrillation (NVAF), according to a study published in Circulation in mid-June.
Tennessee pharmacy board strengthens compounding rules
Less than a month after FDA warned of an outbreak following steroid injections from a compounding pharmacy there, the Tennessee Board of Pharmacy (TBOP) strengthened its oversight of compounding pharmacies.
Anticoagulant dosing in obesity should be individualized and drug-specific